|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910830983303321 |
|
|
Titolo |
SSRIs in depression and anxiety / / edited by Stuart A. Montgomery, Johan A. den Boer |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Chichester, [England] : , : John Wiley & Sons, LTD, , 2001 |
|
©2001 |
|
|
|
|
|
|
|
|
|
ISBN |
|
1-280-55541-6 |
9786610555413 |
0-470-84651-8 |
0-470-85373-5 |
|
|
|
|
|
|
|
|
Edizione |
[2nd ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (226 p.) |
|
|
|
|
|
|
Collana |
|
Perspectives in Psychiatry ; ; Volume 8 |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Serotonin uptake inhibitors |
Anxiety - Chemotherapy |
Depression, Mental - Chemotherapy |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references at the end of each chapters and index. |
|
|
|
|
|
|
|
|
Nota di contenuto |
|
SSRIs in Depression and Anxiety; Contents; List of contributors; 1 Epidemiology of depression and anxiety disorders; 2 Biological aspects of anxiety disorders and depression; 3 Comorbidity of depression and anxiety disorders; 4 Utility of SSRIs in anxious depression; 5 SSRIs in panic disorder; 6 Social anxiety disorder treatment: role of SSRIs; 7 SSRIs in obsessive-compulsive disorder; 8 Serotonin and serotonergic drugs in post-traumatic stress disorder; 9 SSRIs in the treatment of generalized anxiety disorder; Index |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
SSRIs have been used as an effective treatment for depression for many years, but have recently become more widely used in the treatment of many other disorders including post traumatic stress, generalised anxiety disorder and obsessive compulsive disorder. This second edition will provide a timely update on the use of SSRIs in anxiety as their application in this area becomes more common and drug companies seek more widespread uses to maintain sales as SSRIs begin to loose basic patent protection. |
|
|
|
|
|
|
|